Compare Albertsons Companies Inc (ACI) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs DexCom, Inc. — how do they compare? Albertsons Companies Inc trades at $12.15 (market cap $5.95B), while DexCom, Inc. trades at $90.11 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 5.7× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays a 5.55% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| ACI | DXCM | |
|---|---|---|
Market Cap | $5.95B | $33.79B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $89.53 |
52-Week Low | $11.03 | $54.84 |
Enterprise Value | $21.35B | $33.24B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $12.135, showing minimal daily movement with a 0.04% gain. The stock faces bearish technical signals despite recent insider buying by the CEO and CFO. Fundamentals reveal declining profitability with net income margin at just 0.08% and falling revenue growth, though valuation metrics like P/S of 0.08 appear attractive. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple law firm investigations into potential securities violations.
ACI presents a high-risk opportunity with conflicting signals. While insider purchases and low valuation multiples suggest potential value, deteriorating margins, earnings misses, and legal scrutiny create significant headwinds. The stock's near-term trajectory depends on successful execution of the ACI Edge restructuring and digital initiatives to reverse profitability declines.
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
